文献速递临床试验与 GCP基础与转化研究

药物条件化治疗新发类风湿关节炎:随机对照试验方案

Pharmacological conditioning in the treatment of recent-onset rheumatoid arthritis: a randomized controlled trial study protocol.
PubMed 文献 · Trials · 2020-01-06

本方案为多中心随机对照试验,纳入新发类风湿关节炎患者,先接受16周标准化治疗(甲氨蝶呤15 mg/周及泼尼松逐渐减量),临床缓解者随机分为对照组(继续甲氨蝶呤15 mg/周)和药物条件化组(甲氨蝶呤高低剂量交替),两组各期累积剂量相同,主要比较12个月时无药临床缓解比例。

要点

  • 药物条件化组采用甲氨蝶呤高低剂量交替方案,与对照组累积剂量相同。
  • 主要结局为12个月时无药临床缓解比例,采用逻辑回归比较两组。
  • 次要结局包括临床功能、实验室评估和自我报告指标,每4个月评估至18个月。

核心结论

  • 本试验旨在验证药物条件化能否增强新发类风湿关节炎的长期治疗效果。

研究设计与样本

  • 多中心随机对照临床试验,纳入新发类风湿关节炎患者,先接受16周标准化治疗。
  • 临床缓解者随机分为对照组(甲氨蝶呤15 mg/周)和药物条件化组(甲氨蝶呤高低剂量交替)。

关键数值与推荐

  • 临床缓解基于风湿科医生判断且44关节疾病活动度评分(DAS44)低于1.6。
  • 标准化治疗包括甲氨蝶呤15 mg/周和泼尼松60 mg或30 mg的逐渐减量方案。

临床怎么用

  • 若证实有效,药物条件化可作为一种创新治疗策略优化长期药物疗效。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: In pharmacological conditioning associations are formed between the effects of medication and contextual factors related to the medication. Pharmacological conditioning with placebo medication can result in comparable treatment effects and reduced side effects compared to regular treatment in various clinical populations, and may be applied to achieve enhanced drug effects. In the current study protocol, pharmacological conditioning is applied to achieve enhanced treatment effects in patients with recent-onset rheumatoid arthritis (RA). The results from this study broaden the knowledge on the potential of pharmacological conditioning and provide a potential innovative treatment option to optimize long-term pharmacological treatment effectiveness for patients with inflammatory conditions, such as recent-onset RA. METHODS: A multicenter, randomized controlled clinical trial is conducted in patients with recent-onset RA. Participants start on standardized pharmacological treatment for 16 weeks, which consists of methotrexate (MTX) 15 mg/week and a tapered schedule of prednisone 60 mg or 30 mg. After 4 months, participants in clinical remission (based on the rheumatologist's opinion and a targeted score below 1.6 on a 44-joint disease activity score (DAS44)) are randomized to 1 of 2 groups: (1) the control group (C), which continues with a standardized treatment schedule of MTX 15 mg/week or (2) the pharmacological conditioning group (PC), which receives an MTX treatment schedule in alternating high and low dosages. In the case of persistent clinical remission after 8 months, treatment is tapered and discontinued linearly in the C group and variably in the PC group. Both groups receive the same cumulative amount of MTX during each period. Logistic regression analysis is used to compare the proportion of participants with drug-free clinical remission after 12 months between the C group and the PC group. Secondary outcome measures include clinical functioning, laboratory assessments, and self-reported measures after each 4-month period up to 18 months after study start. DISCUSSION: The results from this study broaden the knowledge on the potential of pharmacological conditioning and provide a potential innovative treatment option to optimize long-term pharmacological treatment effectiveness in patients with inflammatory conditions, such as recent-onset RA. TRIAL REGISTRATION: Netherlands Trial Register, NL5652. Registered on 3 March 2016.

来源:Trials,查看原文。版权归原作者所有。

引用

  1. Manaï M, van Middendorp H, Veldhuijzen DS, et al. Pharmacological conditioning in the treatment of recent-onset rheumatoid arthritis: a randomized controlled trial study protocol. Trials. 2020. PMID: 31907004. doi:10.1186/s13063-019-3777-6

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。